Inflammatory Markers in Matched Plasma and Cerebrospinal Fluid from Patients with Alzheimer’s DiseaseSun Y.-X. · Minthon L. · Wallmark A. · Warkentin S. · Blennow K. · Janciauskiene S.
aDepartment of Medicine, Malmö University Hospital, bDepartment of Psychiatry, Neuropsychiatric Clinic, Malmö University Hospital, Malmö, cDepartment of Clinical Neuroscience, Unit of Neurochemistry, UniversityofGöteborg, Göteborg,Sweden
It has been suggested that a number of molecules associated with inflammation are involved in the pathogenesis of Alzheimer’s disease (AD). We measured the levels of α1-antichymotrypsin (ACT), α1-antitrypsin (AAT), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1) and oxidised low-density lipoprotein (oxLDL) in matched cerebrospinal fluid (CSF) and plasma of 141 patients with probable AD. We found a significant relationship between CSF and plasma levels of ACT (r = 0.4, p < 0.001), IL-6 (r = 0.74, p < 0.001), MCP-1 (r = 0.71, p < 0.001), and a borderline relationship between CSF and plasma oxLDL (r = 0.22, p < 0.05). In addition, linear regression analysis revealed a positive correlation between levels of CSF-ACT and oxLDL (p < 0.001), but an inverse relation between levels of CSF ACT, CSF AAT and MCP-1 (p < 0.001). A significant correlation was also found between levels of CSF ACT, oxLDL and the ratio of CSF to serum albumin, which is used as a measure of the blood-brain barrier function. Our data extend previous reports regarding the inflammatory markers in the plasma and CSF of patients with AD and provide good evidence that levels of ACT, IL-6, MCP-1 and oxLDL in plasma and CSF might be candidates as biomarkers for monitoring the inflammatory process in AD.
|Direct payment||This item at the regular price: USD 38.00|
|Payment from account||With a Karger Pay-per-View account (down payment USD 150)
you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50